三维质谱成像技术在 TKI 中的应用。

Application of 3D Mass Spectrometry Imaging to TKIs.

机构信息

Department of Oncology, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.

Department of Environmental Health Sciences, Mass Spectrometry Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.

出版信息

Clin Pharmacol Ther. 2017 Nov;102(5):748-751. doi: 10.1002/cpt.786.

DOI:10.1002/cpt.786

PMID:29023728

Abstract

Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by MSI provides a more informative description of the tumor drug distribution compared to the high-performance liquid chromatography method, highlighting the heterogeneity of intratumor drug concentration. This additional information can be important in understanding chemoresistance to target agents. Here, we present the 3D visualization of the tyrosine kinase inhibitor (TKI), imatinib, in a xenograft model of resistant malignant pleural mesothelioma.

摘要

质谱成像（MSI）允许根据其分子质量可视化组织切片中的内源性和外源性化合物。与高效液相色谱法相比，MSI 的 3D 重建提供了对肿瘤药物分布的更具信息量的描述，突出了肿瘤内药物浓度的异质性。这种附加信息对于理解针对药物的化学抗性可能很重要。在这里，我们在耐药性恶性胸膜间皮瘤的异种移植模型中展示了酪氨酸激酶抑制剂（TKI）伊马替尼的 3D 可视化。